Literature DB >> 15941894

Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome.

Rajagopal V Sekhar1, Farook Jahoor, Henry J Pownall, Khaleel Rehman, John Gaubatz, Dinakar Iyer, Ashok Balasubramanyam.   

Abstract

BACKGROUND: The pathogenesis of hypertriacylglycerolemia, a characteristic feature of HIV lipodystrophy syndrome (HLS), is incompletely understood. One mechanism is accelerated lipolysis in the fasted state, but the severity of the hypertriacylglycerolemia suggests that additional underlying abnormalities may exist in the disposal of dietary fat.
OBJECTIVE: Our objective was to investigate abnormalities in dietary fat disposal in the pathogenesis of hypertriacylglycerolemia in HLS.
DESIGN: We studied 6 nondiabetic men with HLS and 6 men without HIV matched for age and body mass index as control subjects for 8 h after consumption of an isocaloric meal containing 2 g labeled [(13)C(3)]tripalmitin. Chylomicron-triacylglycerol disposal was estimated from labeled [(13)C(1)]palmitate in the plasma chylomicron fraction, and [(13)C(1)]palmitate oxidation was estimated from the (13)CO(2) enrichment in the breath and CO(2) production, over 8 h after the meal.
RESULTS: HLS patients had significantly elevated concentrations of fasting plasma triacylglycerols in both chylomicron (x + SE: 100.3 +/- 49.5 compared with 29.2 +/- 2.2 mg/dL; P < 0.01) and VLDL (82.4 +/- 39.0 compared with 10.8 +/- 2.8 mg/dL; P < 0.01) fractions. Chylomicron-triacylglycerol-derived [(13)C(1)]palmitate disposal was markedly lower in the HLS patients (3.09 +/- 0.41 compared with 6.42 +/- 0.18 mmol [(13)C(1)]palmitate/8 h; P < 0.001) in the 8-h postmeal period. Further, HLS patients had lowered storage of chylomicron-triacylglycerols (0.74 +/- 0.38 compared with 5.05 +/- 0.16 mmol; P < 0.0001) and elevated plasma [(13)C(1)]palmitate concentrations (2.01 +/- 0.27 compared with 1.18 +/- 0.16 mmol; P < 0.05) 8 h after the meal.
CONCLUSIONS: Patients with HLS have key defects that markedly impair postprandial disposal and storage of chylomicron-triacylglycerols. These defects contribute significantly to hypertriacylglycerolemia in HLS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15941894     DOI: 10.1093/ajcn/81.6.1405

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  23 in total

1.  Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients.

Authors:  Sirirat Likanonsakul; Tippawan Rattanatham; Siriluk Feangvad; Sumonmal Uttayamakul; Wisit Prasithsirikul; Somkid Srisopha; Ravee Nitiyanontakij; Pimrapat Tengtrakulcharoen; Maciej Tarkowski; Agostino Riva; Emi E Nakayama; Tatsuo Shioda
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-20       Impact factor: 2.205

Review 2.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.

Authors:  Mustafa A Noor
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

Review 3.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

4.  Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.

Authors:  Ashok Balasubramanyam; Ivonne Coraza; E O'Brian Smith; Lynne W Scott; Payal Patel; Dinakar Iyer; Addison A Taylor; Thomas P Giordano; Rajagopal V Sekhar; Pamela Clark; Edith Cuevas-Sanchez; Swarna Kamble; Christie M Ballantyne; Henry J Pownall
Journal:  J Clin Endocrinol Metab       Date:  2011-05-11       Impact factor: 5.958

Review 5.  Adipose Tissue in HIV Infection.

Authors:  John R Koethe
Journal:  Compr Physiol       Date:  2017-09-12       Impact factor: 9.090

Review 6.  Pathogenesis and treatment of HIV lipohypertrophy.

Authors:  Vivien L Leung; Marshall J Glesby
Journal:  Curr Opin Infect Dis       Date:  2011-02       Impact factor: 4.915

Review 7.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

8.  Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Authors:  Catherine N Vu; Raul Ruiz-Esponda; Eric Yang; Evelyn Chang; Baiba Gillard; Henry J Pownall; Ron C Hoogeveen; Ivonne Coraza; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2013-03-19       Impact factor: 8.694

Review 9.  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Authors:  Erdembileg Anuurad; Alison Semrad; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

10.  The effect of IL6-174C/G polymorphism on postprandial triglyceride metabolism in the GOLDN studyboxs.

Authors:  Jian Shen; Donna K Arnett; Pablo Pérez-Martínez; Laurence D Parnell; Chao-Qiang Lai; James M Peacock; James E Hixson; Michael Y Tsai; Robert J Straka; Paul N Hopkins; José M Ordovás
Journal:  J Lipid Res       Date:  2008-04-16       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.